Raptor Pharma Corp. (RPTP) announced that on December 22, it completed its registered direct offering with institutional investors, raising an aggregate amount of approximately $7.5 million of gross proceeds, before placement agent fees and offering expenses, through the sale of 3,747,558 units.
Christopher Starr, CEO, said, "This U.S.-based financing is a major milestone for Raptor, as the proceeds from this offering will enable us to move all of our principal clinical programs forward, focusing on our lead compound, DR Cysteamine, for the treatment of cystinosis. We look forward to executing our pivotal Phase 3 clinical trial for cystinosis".
For comments and feedback: editorial@rttnews.com